Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Michael FeldEVP, Chief Revenue Officer | Becton DickinsonBDX | Open-market sale10b5-1 plan | 09/28 | 09/29 | 76 sh | $183.70 | $13,961.2 | −0.4% |
Michael FeldEVP, Chief Revenue Officer | Becton DickinsonBDX | Open-market sale10b5-1 plan | 06/26 | 06/26 | 75 sh | $152.80 | $11,460 | −0.4% |
Michael David GarrisonEVP & Pres Med.Essntl&BioPharm | Becton DickinsonBDX | Open-market sale10b5-1 plan | 06/24 | 06/25 | 1,100 sh | $145.66 | $160,226 | −7.7% |
Michael David GarrisonEVP & Pres Med.Essntl&BioPharm | Becton DickinsonBDX | Open-market sale10b5-1 plan | 06/10 | 06/11 | 1,100 sh | $151.48 | $166,628 | −7.2% |
Thomas E. Polen Jr.Chairman, CEO and President | Becton DickinsonBDX | Open-market sale10b5-1 plan | 06/01 | 06/03 | 2,764 sh | $146.35 | $404,511.4 | −2.4% |
Michael FeldEVP, Chief Revenue Officer | Becton DickinsonBDX | Open-market sale10b5-1 plan | 05/26 | 05/27 | 75 sh | $147.35 | $11,051.25 | −0.4% |
Michael FeldEVP, Chief Revenue Officer | Becton DickinsonBDX | Open-market sale10b5-1 plan | 04/27 | 04/28 | 74 sh | $151.94 | $11,243.56 | −0.3% |
Michael FeldEVP, Chief Revenue Officer | Becton DickinsonBDX | Open-market sale10b5-1 plan | 03/26 | 03/27 | 75 sh | $156.83 | $11,762.25 | −0.4% |
Michael FeldEVP, Chief Revenue Officer | Becton DickinsonBDX | Open-market sale10b5-1 plan | 02/26 | 02/27 | 75 sh | $181.84 | $13,638 | −0.4% |
Bertram L. ScottDirector | Becton DickinsonBDX | Open-market sale | 02/18 | 02/18 | 953 sh | $182.61 | $174,027.33 | −2.5% |
Michael FeldEVP, CRO & Pres. Life Sciences | Becton DickinsonBDX | Open-market sale10b5-1 plan | 01/26 | 01/28 | 75 sh | $202.73 | $15,204.75 | −0.5% |
Becton DickinsonBDX | Open-market sale10b5-1 plan | 01/15 | 01/16 | 1,610 sh2 trades | $207.46avg. | $334,005.4 | −11.7% | |
Michael FeldEVP, CRO & Pres. Life Sciences | Becton DickinsonBDX | Open-market sale10b5-1 plan | 25/12/26 | 25/12/29 | 74 sh | $196.08 | $14,509.92 | −0.4% |
Michael David GarrisonEVP & Pres Med.Essntl&BioPharm | Becton DickinsonBDX | Open-market sale10b5-1 plan | 25/12/17 | 25/12/17 | 629 sh | $196.03 | $123,302.87 | −4.6% |
Michael FeldEVP, CRO & Pres. Life Sciences | Becton DickinsonBDX | Open-market sale10b5-1 plan | 25/12/01 | 25/12/02 | 75 sh | $193.36 | $14,502 | −0.5% |
Bertram L. ScottDirector | Becton DickinsonBDX | Open-market sale | 25/11/07 | 25/11/07 | 217 sh | $176.58 | $38,317.86 | −0.6% |
Michael FeldEVP & President, Life Sciences | Becton DickinsonBDX | Open-market sale10b5-1 plan | 25/10/27 | 25/10/28 | 57 sh | $186.01 | $10,602.57 | −0.7% |
Michael FeldEVP & President, Life Sciences | Becton DickinsonBDX | Open-market sale10b5-1 plan | 25/09/26 | 25/09/29 | 58 sh | $181.03 | $10,499.74 | −0.7% |
Claire FraserDirector | Becton DickinsonBDX | Open-market sale | 25/09/10 | 25/09/11 | 917 sh | $187.50 | $171,937.5 | −4.0% |
Michael FeldEVP & President, Life Sciences | Becton DickinsonBDX | Open-market sale10b5-1 plan | 25/08/22 | 25/08/26 | 57 sh | $197.99 | $11,285.43 | −0.7% |
